VivoSim (VIVS, Financial) Labs recently showcased its NAMkind platform for liver toxicology at the Digestive Disease Week Conference. The platform, available to pharmaceutical companies, demonstrated exceptional predictive accuracy when tested against various liver compounds. Impressively, the NAMkind platform achieved an 87.5% success rate in identifying challenging cases of liver toxicity. These cases included drugs with unexpected liver toxicity discovered during clinical trials or those withdrawn from the market due to later emergence of liver toxicity issues.
The platform's ability to correctly identify 87.5% of known liver-toxic drugs as liver toxic is a notable achievement, representing what is known as the sensitivity of the system, marking it as a leader in the field. Additionally, the platform exhibited a specificity of 100%, accurately distinguishing all non-toxic compounds without error. This accomplishment underscores the reliability of NAMkind in liver toxicity predictions, offering significant benefits to the pharmaceutical industry.
